AFMD
Price:
$2.87
Market Cap:
$41.70M
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid ...[Read more]
Industry
Biotechnology
IPO Date
2014-09-12
Stock Exchange
NASDAQ
Ticker
AFMD
According to Affimed N.V.’s latest financial reports and current stock price. The company's current Enterprise Value is 47.19M. This represents a change of -22.26% compared to the average of 60.70M of the last 4 quarters.
The mean historical Enterprise Value of Affimed N.V. over the last ten years is 110.49M. The current 47.19M Enterprise Value has changed 4.17% with respect to the historical average. Over the past ten years (40 quarters), AFMD's Enterprise Value was at its highest in in the June 2021 quarter at 645.78M. The Enterprise Value was at its lowest in in the March 2023 quarter at -36408616.75.
Average
110.49M
Median
69.68M
Minimum
-7236343.14
Maximum
401.16M
Discovering the peaks and valleys of Affimed N.V. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 324.68%
Maximum Annual Enterprise Value = 401.16M
Minimum Annual Increase = -1002.36%
Minimum Annual Enterprise Value = -7236343.14
Year | Enterprise Value | Change |
---|---|---|
2023 | 65.30M | -1002.36% |
2022 | -7236343.14 | -101.80% |
2021 | 401.16M | 59.24% |
2020 | 251.93M | 288.10% |
2019 | 64.91M | -12.34% |
2018 | 74.05M | 324.68% |
2017 | 17.44M | -32.81% |
2016 | 25.95M | -77.34% |
2015 | 114.54M | 18.25% |
2014 | 96.86M | -3.18% |
The current Enterprise Value of Affimed N.V. (AFMD) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
153.07M
5-year avg
155.21M
10-year avg
110.49M
Affimed N.V.’s Enterprise Value is less than TCR2 Therapeutics Inc. (79.12M), greater than Pieris Pharmaceuticals, Inc. (3.17M), less than ADC Therapeutics SA (271.89M), less than Agenus Inc. (89.67M), greater than X4 Pharmaceuticals, Inc. (40.87M), less than Terns Pharmaceuticals, Inc. (230.61M), less than Day One Biopharmaceuticals, Inc. (945.30M), less than PDS Biotechnology Corporation (53.85M), less than Inozyme Pharma, Inc. (192.45M), greater than Leap Therapeutics, Inc. (39.10M), less than Adaptimmune Therapeutics plc (72.91M), less than Corvus Pharmaceuticals, Inc. (556.64M), greater than Aptose Biosciences Inc. (14.20M), greater than eFFECTOR Therapeutics, Inc. (4.74M), greater than Elevation Oncology, Inc. (19.82M), less than Mereo BioPharma Group plc (499.63M), greater than Hepion Pharmaceuticals, Inc. (5.39M),
Company | Enterprise Value | Market cap |
---|---|---|
79.12M | $58.11M | |
3.17M | $22.54M | |
271.89M | $214.65M | |
89.67M | $79.29M | |
40.87M | $60.08M | |
230.61M | $499.44M | |
945.30M | $1.37B | |
53.85M | $78.93M | |
192.45M | $170.24M | |
39.10M | $101.54M | |
72.91M | $165.02M | |
556.64M | $560.97M | |
14.20M | $3.47M | |
4.74M | $941.00 | |
19.82M | $37.00M | |
499.63M | $579.02M | |
5.39M | $4.66M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Affimed N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Affimed N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Affimed N.V.'s Enterprise Value?
What is the highest Enterprise Value for Affimed N.V. (AFMD)?
What is the 3-year average Enterprise Value for Affimed N.V. (AFMD)?
What is the 5-year average Enterprise Value for Affimed N.V. (AFMD)?
How does the current Enterprise Value for Affimed N.V. (AFMD) compare to its historical average?